Shetty S S, Okada T, Webb R L, DelGrande D, Lappe R W
Research Department, Pharmaceuticals Division, CIBA-GEIGY Corp., Summit, NJ 07901.
Biochem Biophys Res Commun. 1993 Mar 15;191(2):459-64. doi: 10.1006/bbrc.1993.1240.
IRL 1620 (Suc-[Glu9,Ala11,15]-ET-1 (8-21)) (0.1 nM - 1 microM), a novel ETB-selective endothelin (ET) agonist, produced endothelium-dependent relaxations in precontracted rabbit mesenteric artery (2 nM, EC50) and endothelium-independent contractions in porcine coronary artery (18 nM, EC50). ET-3 (0.1 nM-10 nM) produced qualitatively similar responses in the two tissues. The maximal contractions induced by IRL 1620 or ET-3 were substantially smaller (< 20%) than that produced by ET-1. BQ-123 (1 microM), an ETA receptor antagonist, inhibited responses to ET-1 without affecting IRL 1620- or ET-3-induced responses in either tissue. Thus functionally distinct ETB receptors mediating vasodilator and vasoconstrictor effects are located on the vascular endothelium and smooth muscle, respectively. The overall effect of ETB receptor activation on vascular tone is tissue-specific and presumably reflects differing receptor distribution at the two sites.
IRL 1620(Suc-[Glu9,Ala11,15]-ET-1 (8 - 21))(0.1纳摩尔至1微摩尔)是一种新型的ETB选择性内皮素(ET)激动剂,在预先收缩的兔肠系膜动脉中产生内皮依赖性舒张(2纳摩尔,半数有效浓度),在猪冠状动脉中产生非内皮依赖性收缩(18纳摩尔,半数有效浓度)。ET-3(0.1纳摩尔至10纳摩尔)在这两种组织中产生性质相似的反应。IRL 1620或ET-3诱导的最大收缩幅度比ET-1产生的最大收缩幅度小得多(<20%)。ETA受体拮抗剂BQ-123(1微摩尔)抑制对ET-1的反应,而不影响IRL 1620或ET-3在任一组织中诱导的反应。因此,介导血管舒张和血管收缩作用的功能不同的ETB受体分别位于血管内皮和平滑肌上。ETB受体激活对血管张力的总体影响具有组织特异性,可能反映了这两个部位不同的受体分布情况。